Skip to main content
Canna~Fangled Abstracts

Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ 9-tetrahydrocannabinol: a pilot study

By October 18, 2021October 23rd, 2021No Comments
. 2021 Oct 18.

doi: 10.1007/s00228-021-03232-8.

Online ahead of print.
Erica N Peters 1, Laura MacNair 2, Irina Mosesova 2, Uwe Christians 3, Cristina Sempio 3, Jost Klawitter 3, M Hunter Land 2, Mark A Ware 2, Cynthia Turcotte 2, Marcel O Bonn-Miller 2
Affiliations 

Abstract

Purpose: Cannabichromene (CBC) is a phytocannabinoid commonly found in cannabis, yet its acute post-dose pharmacokinetics (PK) have not been examined in humans. This is a secondary data analysis from a trial investigating Spectrum Yellow oil, an oral cannabis product used for medical purposes that contained 20 mg cannabidiol (CBD), 0.9 mg Δ9-tetrahydrocannabinol (THC), and 1.1 mg CBC, per 1 mL of oil.

Methods: Participants (N = 43) were randomized to one of 5 groups: 120 mg CBD, 5.4 mg THC, and 6.6 mg CBC daily; 240 mg CBD, 10.8 mg THC, and 13.2 mg CBC daily; 360 mg CBD, 16.2 mg THC, and 19.8 mg CBC daily; 480 mg CBD, 21.6 mg THC, and 26.4 mg CBC daily; or placebo. Study medication was administered every 12 h for 7 days. Plasma CBC concentrations were analyzed by a validated two-dimensional high-performance liquid chromatography-tandem mass spectrometry assay.

Results: After a single dose and after the final dose, the Cmax of CBC increased by 1.3-1.8-fold for each twofold increase in dose; the tmax range was 1.6-4.3 h. Based on the ratio of administered CBD, THC, and CBC to the plasma concentration, the dose of CBD was 18 times higher than the dose of CBC, yet the AUC0-t of CBD was only 6.6-9.8-fold higher than the AUC0-t of CBC; the dose of THC was similar to the dose of CBC, yet THC was quantifiable in fewer plasma samples than was CBC.

Conclusions: CBC may have preferential absorption over CBD and THC when administered together.

Trial registration: Australian New Zealand Clinical Trials Registry #ACTRN12619001450101, registered 18 October 2019.

 

Keywords: Cannabichromene, Cannabis, Pharmacokinetics, Phytocannabinoid

References

    1. Hill KP (2019) Medical use of cannabis in 2019. JAMA. https://doi.org/10.1001/jama.2019.11868 – DOI – PubMed
    1. Izzo AA, Borrelli F, Capasso R et al (2009) Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30:515–527. https://doi.org/10.1016/j.tips.2009.07.006 – DOI – PubMed
    1. Turner CE, Elsohly MA, Boeren EG (1980) Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J Nat Prod 43:169–234. https://doi.org/10.1021/np50008a001 – DOI – PubMed
    1. Mehmedic Z, Chandra S, Slade D et al (2010) Potency trends of Delta9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 55:1209–1217. https://doi.org/10.1111/j.1556-4029.2010.01441.x – DOI – PubMed
    1. Potter DJ, Clark P, Brown MB (2008) Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 53:90–94. https://doi.org/10.1111/j.1556-4029.2007.00603.x – DOI – PubMed

Leave a Reply